Imidazoline NNC77-0074 stimulates insulin secretion and inhibits glucagon release by control of Ca2+-dependent exocytosis in pancreatic α- and β-cells-Reference-Cited by-同舟云学术

Imidazoline NNC77-0074 stimulates insulin secretion and inhibits glucagon release by control of Ca2+-dependent exocytosis in pancreatic α- and β-cells

Published:2003-04 Issue:1-2 Volume:466 Page:213-221
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Høy Marianne,Olsen Hervør L.,Andersen Henrik S.,Bokvist Krister,Buschard Karsten,Hansen John,Jacobsen Palle,Petersen Jacob S.,Rorsman Patrik,Gromada Jesper

Publisher

Elsevier BV

Subject

Pharmacology

Reference27 articles.

1. Exocytosis elicited by action potentials and voltage-clamp calcium currents in individual mouse pancreatic β-cells;Ämmälä;J. Physiol.,1993

2. The stimulatory action of tolbutamide on Ca2+-dependent exocytosis in pancreatic β cells is mediated by a 65-kDa mdr-like P-glucoprotein;Barg;Proc. Natl. Acad. Sci.,1999

3. Priming of insulin granules for exocytosis by granular Cl− uptake and acidification;Barg;J. Cell Sci.,2001

4. Characterisation of sulphonylurea and ATP-regulated K+-channels in rat pancreatic α-cells;Bokvist;Pflügers Arch.,1999

5. The sulfonylurea controversy: more questions from the heart;Brady;JACC,1998

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands;Mini-Reviews in Medicinal Chemistry;2012-11-01

2. Imidazoline receptors ligands;Chemical Industry;2012

3. Docking and molecular dynamics studies on the interaction of four imidazoline derivatives with potassium ion channel (Kir6.2);Molecular Simulation;2010-02

4. Overexpression of Alpha2A-Adrenergic Receptors Contributes to Type 2 Diabetes;Science;2010-01-08

5. Selective Enhancement of Nutrient-Induced Insulin Secretion by ATP-Sensitive K+ Channel-Blocking Imidazolines;Journal of Pharmacology and Experimental Therapeutics;2009-09-10